TK IMPACT: Treatment Monitoring of Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Metastatic Breast Cancer (MBC) Patients Receiving CDK 4/6 Inhibitors (CDK4/6i) with DiviTum® Thymidine Kinase 1 Activity

被引：1
|
作者：
Bagegni, Nusayba A.
Grigsby, Isabella
Nehring, Leslie
Luo, Jingqin
Carson, Jennifer Powers
Gibson, David W.
Horvath, Meghan
Clifton, Katherine K.
Ademuyiwa, Foluso O.
Suresh, Rama
Frith, Ashley
Davis, Andrew A.
Peterson, Lindsay L.
Bose, Ron
Williams, Amy
Bergqvist, Mattias
Ma, Cynthia
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT3-11-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-11-01
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Biomarkers of response to CDK4/6 inhibitor (CDK4/6i) in hormone receptor (HR) positive and HER2-positive breast cancer (BC) patient-derived xenografts (PDX)
    Palafox, Marta
    Herrera-Abreu, Maria Teresa
    Bellet, Meritxell
    Oliveira, Mafalda
    Bruna, Alejandra
    Rodriguez, Olga
    Guzman, Marta
    Grueso, Judit
    Vilaplana, Cristina
    Arribas, Joaquin
    di Tomaso, Emmanuelle
    Su, Faye
    Caldas, Carlos
    Turner, Nicholas C.
    Dienstmann, Rodrigo
    Baselga, Jose
    Scaltriti, Maurizio
    Cortes, Javier
    Saura, Cristina
    Serra, Violeta
    CANCER RESEARCH, 2018, 78 (13)
  • [32] Blood tumor mutational burden (bTMB) and blood copy number burden (bCNB) by genome-wide circulating tumor DNA (ctDNA) assessment predict outcome and resistance in hormone-receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitor (CDK4/6i)
    Davis, Andrew
    Luo, Jingqin
    Zheng, Tiantian
    Tan, Lu
    Wang, Amy
    Suresh, Rama
    Ademuyiwa, Foluso
    Rigden, Caron
    Rearden, Timothy
    Clifton, Katherine
    Weilbaecher, Katherine
    Frith, Ashley
    Tandra, Pavan K.
    Summa, Tracy
    Haas, Brittney
    Thomas, Shana
    Hernandez-Aya, Leonel
    Peterson, Lindsay
    Luo, Shujun
    King, Bonnie L.
    Jia, Shidong
    Yu, Jianjun
    Du, Pan
    Krishnamurthy, Jairam
    Ma, Cynthia X.
    Dai, C.
    CANCER RESEARCH, 2022, 82 (04)
  • [33] Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the United States
    Ravi K. Goyal
    Holly M. Holmes
    Hua Chen
    Susan Abughosh
    Sean D. Candrilli
    Michael L. Johnson
    Breast Cancer Research and Treatment, 2023, 198 : 159 - 166
  • [34] CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS (CDK4/6I) IN HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED/METASTATIC BREAST CANCER (A/MBC): A SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE (RWE) STUDIES
    Harbeck, N.
    Bartlett, M.
    Spurden, D.
    Hooper, B.
    Zhan, L.
    Rosta, E.
    Cameron, C.
    Mitra, D.
    Zhou, A.
    VALUE IN HEALTH, 2020, 23 : S27 - S27
  • [35] CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
    Di Cosimo, Serena
    Porcu, Luca
    Cardoso, Fatima
    BREAST, 2021, 55 : 75 - 78
  • [36] CDK4/6 inhibitors in HER2-positive breast cancer
    Corona, Silvia Paola
    Ravelli, Andrea
    Cretella, Daniele
    Cappelletti, Maria Rosa
    Zanotti, Laura
    Dester, Martina
    Gobbi, Angela
    Petronini, Pier Giorgio
    Generali, Daniele
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 112 : 208 - 214
  • [37] HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS
    Burne, R.
    Balu, S.
    Guerin, A.
    Liang, Y.
    Schloessmann, R.
    Bungay, R.
    Paul, M. L.
    VALUE IN HEALTH, 2020, 23 : S44 - S44
  • [38] A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
    Rugo, H.
    Tolaney, S.
    Dickler, M.
    Kabos, P.
    Ho, C-L
    Wildiers, H.
    Jerusalem, G.
    Ales-Martinez, J. E.
    Hossain, A.
    Johnston, E.
    Gianni, L.
    CANCER RESEARCH, 2017, 77
  • [39] Impact of metastases directed radiation therapy on CDK4/6 inhibitors dose reduction and treatment discontinuation for metastatic HR+/HER2-breast cancer (MBC).
    Meattini, Icro
    Scoccimarro, Erika
    Saieva, Calogero
    Desideri, Isacco
    Visani, Luca
    Dominici, Luca
    Cerbai, Cecilia
    Aquilano, Michele
    Ciccone, Lucia Pia
    Palmieri, Valeria Emma
    Scotti, Vieri
    Nori, Jacopo
    Bernini, Marco
    Orzalesi, Lorenzo
    Sanchez, Luis
    Dieci, Maria Vittoria
    Bianchi, Simonetta
    Livi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Efficacy of first line CDK4/6 inhibitors in HER2-low vs HER2-zero, hormone receptor positive, HER2 negative metastatic breast cancer
    Sanchez-Bayona, Rodrigo
    Teran, Santiago
    De Torre, Ana Sanchez
    Alva, Manuel
    Lema, Laura
    Manso, Luis
    Toledo, Estefania
    Roncero, Ana Maria
    Merino, Cristina
    Martinez, Mario
    Parrilla, Lucia
    Ciruelos, Eva
    Tolosa, Pablo
    CANCER RESEARCH, 2022, 82 (04)
12345